Structured Abstract
Background Rational polypharmacy in abortive medications use is often inevitable for patients with refractory headaches.
Objective We seek to enumerate an exhaustive list of headaches abortive medications that are without drug-drug interactions.
Methods We updated a list of acute medications based on the widely used Jefferson Headache Manual with novel abortive medications including ubrogepant, lasmiditan, and rimegepant. Opioids and barbiturate containing products are excluded. We then conducted an exhaustive search of all pair-wise interactions for this list of medication via DrugBank API. Using this interaction list, we filtered all possible two, three, and four drug combinations of abortive medications. The resultant list of medication was then reapplied to DrugBank to verify the lack of known drug-drug interaction.
Results There are 192 medication combinations that do not contain any drug-drug interactions. Most common elements in these combinations are ubrogepant, prochlorperazine, followed by tizanidine. There are 67 three-drug combinations that do not contain interaction. Only 2 of the four-drug combinations do not yield some form of drug-drug interactions.
Conclusion This list of headaches abortive medications without drug-drug interactions is a useful tool for clinicians seeking to more effectively manage refractory headaches.
Competing Interest Statement
Pengfei Zhang: He has received honorarium from Alder Biopharmaceuticals, Board Vitals, Fieve Clinical Research. He collaborates with Headache Science Incorporated without receiving financial support. Ownership interest in Cymbeline LLC Victor Kaytser: No disclosures.
Clinical Trial
This is not a clinical trial but rather a study of drug interaction database.
Funding Statement
We did not receive any financial support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB is needed given this paper does not involve human subjects.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Input for data is available to the public via DrugBank API.
Abbreviations
- API
- Application Programming Interface
- NSAIDs
- Nonsteroidal Anti-inflammatory Drugs
- FDA
- Food and Drugs Administration
- 5HT1F
- Serotonin receptor 1 F
- CGRP
- calcitonin gene-related peptide
- CYP
- cytochromes P450.
